Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVAsION Study
2024-514476-40-00Phase 4Authorised
- Sponsor
- Labo'Life
- Start
- May 2024
- Modality
- Therapeutic Vaccines → Vaccines & Immunotherapeutics, RNA Therapeutics → Nucleic Acid Therapeutics, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of 2LVERU in verruca, plantar wart and flat wart (3 arms), sponsored by Labo'Life. Primary endpoint: Disappearance of warts at end of treatment. Planned start May 2024; status: authorised.
02
Drugs
2LVERU
03
Conditions
verrucaplantar wartflat wart
Beyond the preview
Go deeper on 2024-514476-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514476-40-00.